Core C. Administrative Core. Darell D. Signer, M.D., Ph.D., Core Leader. Support is requested for an Administrative Core including 0.6 calendar months effort for Dr. Bigner as SRC Program Director/Principal Investigator and for John H. Sampson, MD, PhD, MHScto assist Dr. Bigner and to serve as co-chair of the SRC Operations Committee. Drs. Bigner and Sampson will provide oversight of the scientific and administrative activities of the Specialized Research Center. Dr. Bigner will continue as he has for the past 25 years to chair, along with Dr. Sampson as co-chair, the Operations Committee for the SRC which includes all project and core leaders (Drs. Zalutsky, Reardon, and McLendon). Together they will foster communication and collaboration between the projects and cores and monitor and assess progress. Drs. Bigner and Sampson will meet weekly with project and core leaders and will serve as the editorial review team for all publications resulting from SRC activities. Drs. Bigner and Sampson will plan and coordinate regular seminars with the SRC, which will include internal and external speakers, and which are a part of the monthly Neuro-Oncology Program Seminar Series. Drs. Bigner and Sampson will coordinate the participation of SRC investigators in national and international workshops, conferences, and meetings on brain tumor research. They also will coordinate all the activities of the SRC Internal and External Advisory Committees and will serve as SRC liaisons with other appropriate academic units within Duke. Core support is requested for a Staff Specialist, as in previous years of this grant, who will be responsible for scheduling all internal and external meetings, budgetary monitoring, and general administrative assistance. Also, support is requested for a Laboratory Technician, as in previous years of this grant, for maintenance of media solutions, instrument, and glassware preparation. Core C provides support for all three research projects and two cores. Core C functions, for which support is requested in this application, are identical to those of the last five years with the addition of the effort for Dr. Sampson as co-chair of the Operations Committee.

Public Health Relevance

The Administrative Core is necessary to coordinate all of the activities in the projects, all of which are designed to develop new and more effective and less toxic malignant brain tumor treatments. In addition, a specially trained technician is necessary to provide the necessary solutions and ultraclean glassware for the experiments proposed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS020023-30
Application #
8431411
Study Section
Special Emphasis Panel (ZNS1-SRB-G)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
30
Fiscal Year
2013
Total Cost
$131,088
Indirect Cost
$54,815
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Lathia, Justin D; Li, Meizhang; Sinyuk, Maksim et al. (2014) High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep 6:117-29
Koumarianou, Eftychia; Slastnikova, Tatiana A; Pruszynski, Marek et al. (2014) Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic. Nucl Med Biol 41:441-9
Killela, Patrick J; Pirozzi, Christopher J; Healy, Patrick et al. (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515-25
Miao, Hongsheng; Choi, Bryan D; Suryadevara, Carter M et al. (2014) EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One 9:e94281
Choi, Bryan D; Suryadevara, Carter M; Gedeon, Patrick C et al. (2014) Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci 21:189-90
Mehta, Ankit I; Brufsky, Adam M; Sampson, John H (2013) Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev 39:261-9
Chandramohan, Vidyalakshmi; Bao, Xuhui; Kato Kaneko, Mika et al. (2013) Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer 132:2339-48
Yang, Shicheng; Archer, Gary E; Flores, Catherine E et al. (2013) A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. Cancer Immunol Immunother 62:1649-62
Piao, Hailan; Kuan, Chien-Tsun; Chandramohan, Vidya et al. (2013) Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. MAbs 5:748-62
Sanchez-Perez, Luis; Choi, Bryan D; Reap, Elizabeth A et al. (2013) BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother 62:983-7

Showing the most recent 10 out of 115 publications